• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by Revance Therapeutics Inc. (Amendment)

    2/13/24 9:39:24 AM ET
    $RVNC
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $RVNC alert in real time by email
    SC 13G/A 1 polar-rvnc123123a1.htm



     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION
    Washington, DC 20549

     

    SCHEDULE 13G/A

     

    Under the Securities Exchange Act of 1934

    (Amendment No. 1)*



    Revance Therapeutics, Inc.

    (Name of Issuer)

     

    Common Stock, $0.001 par value per share

    (Title of Class of Securities)

     

    761330109

    (CUSIP Number)

     

     

    December 31, 2023
    (Date of Event Which Requires Filing of this Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

    x Rule 13d-1(b)

    o Rule 13d-1(c)

    o Rule 13d-1(d)

     

     

    *The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     


     

    CUSIP No.  761330109
     SCHEDULE 13G/A
    Page 2 of 8 Pages

     

             
    1
    NAME OF REPORTING PERSONS
     
    Polar Capital Holdings Plc
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
    (a) o
    (b) o
     
    3
    SEC USE ONLY
     
     
    4
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
    United Kingdom
    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON
    WITH
    5
    SOLE VOTING POWER
     
    3,169,239
    6
    SHARED VOTING POWER
     
    0
    7
    SOLE DISPOSITIVE POWER
     
    3,169,239
    8
    SHARED DISPOSITIVE POWER
     
    0
    9
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
    3,169,239
    10
    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
     
     
    o
    11
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
     
    3.60%
    12
    TYPE OF REPORTING PERSON
     
    HC

     


     

    CUSIP No.  761330109
     SCHEDULE 13G/A
    Page 3 of 8 Pages

     

             
    1
    NAME OF REPORTING PERSONS
     
    Polar Capital LLP
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
    (a) o
    (b) o
     
    3
    SEC USE ONLY
     
     
    4
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
    United Kingdom
    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON
    WITH
    5
    SOLE VOTING POWER
     
    3,169,239
    6
    SHARED VOTING POWER
     
    0
    7
    SOLE DISPOSITIVE POWER
     
    3,169,239
    8
    SHARED DISPOSITIVE POWER
     
    0
    9
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
    3,169,239
    10
    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
     
     
    o
    11
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
     
    3.60%
    12
    TYPE OF REPORTING PERSON
     
    IA

     


     

     

    CUSIP No. 761330109
     SCHEDULE 13G/A
    Page 4 of 8 Pages

     

    Item 1.(a) Name of Issuer

    Revance Therapeutics, Inc.

    Item 1.(b) Address of Issuer’s Principal Executive Offices

    1222 Demonbreun Street, Suite 2000

    Nashville, TN 37203

    Item 2.(a) Name of Person Filing:

    Polar Capital Holdings Plc

    Polar Capital LLP

     

    Item 2.(b,) Address of Principal Business Office:

    16 Palace Street

    London, SW1E 5JD

     

    Item 2.(c) Citizenship:

    United Kingdom

      

    Item 2.(d) Title of Class of Securities

    Common Stock, $0.001 par value per share (the “Common Stock”)

     

    Item 2.(e) CUSIP No.:

    761330109

     

    CUSIP No.  761330109
     SCHEDULE 13G/A
    Page 5 of 8 Pages

     

     

    Item 3. If this statement is filed pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

      (a) ¨ Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
     
      (b) ¨ Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
     
      (c) ¨ Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
     
      (d) ¨ Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
     
      (e) x An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E);
     
      (f) ¨ An employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F);
     
      (g) x A parent holding company or control person in accordance with §240.13d-1(b)(1)(ii)(G);
     
      (h) ¨ A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
     
      (i) ¨ A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
     
      (j) o A non-U.S. institution in accordance with §240.13d-1(b)(1)(ii)(J);
     
      (k) ¨ A group, in accordance with §240.13d-1(b)(1)(ii)(K). If filing as a non-U.S. institution in accordance with §240.13d-1(b)(1)(ii)(J), please specify the type of institution:                            
           

     

    CUSIP No. 761330109
     SCHEDULE 13G/A
    Page 6 of 8 Pages

     

     

    Item 4. Ownership

    Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1:

    Polar Capital Holdings Plc

    (a) Amount beneficially owned: 3,169,239

    (b) Percent of class: 3.60%*

    (c) Number of shares as to which the person has:

    (i) Sole power to vote or to direct the vote: 3,169,239

    (ii) Shared power to vote or to direct the vote: 0

    (iii) Sole power to dispose or to direct the disposition of: 3,169,239

    (iv) Shared power to dispose or to direct the disposition of: 0

     

    Polar Capital LLP

    (a) Amount beneficially owned: 3,169,239

    (b) Percent of class: 3.60%*

    (c) Number of shares as to which the person has:

    (i) Sole power to vote or to direct the vote: 3,169,239

    (ii) Shared power to vote or to direct the vote: 0

    (iii) Sole power to dispose or to direct the disposition of: 3,169,239

    (iv) Shared power to dispose or to direct the disposition of: 0

     

    * Based on 87,813,480 shares outstanding as reported in the Issuer's Form 10-Q on November 8, 2023.

    Item 5. Ownership of Five Percent or Less of a Class

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following [X].

    Item 6. Ownership of More Than Five Percent on Behalf of Another Person

    Not Applicable.

    Item 7. Identification and Classification of the Subsidiary which Acquired the Security Being Reported on by the Parent Holding Company or Control Person 

    Information for each Subsidiary is incorporated on the respective cover pages..

    Item 8. Identification and Classification of Members of the Group

    Not Applicable.

    Item 9. Notice of Dissolution of Group 

    Not Applicable.

    Item 10. Certification

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

     

     
    CUSIP No. 761330109
     SCHEDULE 13G/A
    Page 7 of 8 Pages

     

     

    SIGNATURE

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    Dated: February 13, 2024

     

     

     

    POLAR CAPITAL HOLDINGS PLC

           
      By:  Nicholas Farren
       

    Name: Nicholas Farren

    Title: Chief Operating Officer

           
     

    POLAR CAPITAL LLP

           
      By:  Nicholas Farren
       

    Name: Nicholas Farren

    Title: Chief Operating Officer

           

     

     
    CUSIP No. 761330109
     SCHEDULE 13G/A
    Page 8 of 8 Pages

     

    Exhibit I

     

    JOINT FILING STATEMENT

     

    PURSUANT TO RULE 13d-1(k)

     

    The undersigned acknowledge and agree that the foregoing statement on SCHEDULE 13G/A, is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on SCHEDULE 13G/A, shall be filed on behalf of each of the undersigned without the necessity of filing additional joint acquisition statements. The undersigned acknowledge that each shall be responsible for the timely filing of such amendments, and for the completeness and accuracy of the information concerning him or it contained therein, but shall not be responsible for the completeness and accuracy of the information concerning the others, except to the extent that he or it knows or has reason to believe that such information is inaccurate.

     

    Dated: February 13, 2024

     

     

     

    POLAR CAPITAL HOLDINGS PLC

           
      By:  Nicholas Farren
       

    Name: Nicholas Farren

    Title: Chief Operating Officer

           
     

    POLAR CAPITAL LLP

           
      By:  Nicholas Farren
       

    Name: Nicholas Farren

    Title: Chief Operating Officer 

           
    Get the next $RVNC alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $RVNC

    DatePrice TargetRatingAnalyst
    1/29/2024$16.00 → $9.00Buy → Neutral
    Mizuho
    1/9/2024$30.00 → $8.00Buy → Neutral
    Goldman
    8/16/2023$20.00Underperform → Neutral
    Exane BNP Paribas
    10/11/2022$27.00Equal-Weight
    Morgan Stanley
    9/22/2022$33.00Buy
    Goldman
    10/26/2021$33.00 → $22.00Overweight
    Barclays
    10/25/2021$17.00Overweight → Equal-Weight
    Wells Fargo
    10/18/2021$45.00 → $25.00Buy
    Needham
    More analyst ratings

    $RVNC
    SEC Filings

    See more
    • SEC Form 15-12G filed by Revance Therapeutics Inc.

      15-12G - Revance Therapeutics, Inc. (0001479290) (Filer)

      2/18/25 6:07:05 AM ET
      $RVNC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SCHEDULE 13G/A filed by Revance Therapeutics Inc.

      SCHEDULE 13G/A - Revance Therapeutics, Inc. (0001479290) (Subject)

      2/13/25 4:02:42 PM ET
      $RVNC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form S-8 POS filed by Revance Therapeutics Inc.

      S-8 POS - Revance Therapeutics, Inc. (0001479290) (Filer)

      2/12/25 8:16:25 AM ET
      $RVNC
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $RVNC
    Financials

    Live finance-specific insights

    See more
    • Crown Laboratories Announces Completion of Acquisition of Revance Therapeutics

      The business combination reinforces Crown's position as a leading, innovative, high-growth aesthetics and skincare company JOHNSON CITY, Tenn., Feb. 6, 2025 /PRNewswire/ -- Crown Laboratories, Inc. ("Crown"), a privately held, global innovative leader in the skincare industry, today announced the successful closing of its acquisition of Revance Therapeutics, Inc. ("Revance") (NASDAQ:RVNC), a biotechnology company aimed at setting the new standard in healthcare with innovative aesthetic and therapeutic offerings. The Offer and the Merger Crown's tender offer to acquire all of

      2/6/25 8:39:00 AM ET
      $RVNC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Revance to Release Second Quarter 2024 Financial Results on Thursday, August 8, 2024

      Conference Call Scheduled for Thursday, August 8, 2024 at 4:30 p.m. ET. Revance Therapeutics, Inc. (NASDAQ:RVNC) today announced that the company will release second quarter 2024 financial results on Thursday, August 8, 2024, after the close of market. Revance will host a corresponding conference call and a live webcast at 1:30 p.m. PT / 4:30 p.m. ET on the same day to discuss the results and provide a corporate update. Individuals interested in listening to the conference call may do so by dialing (833) 470-1428 for U.S callers and (929) 526-1599 or other locations and reference conference ID 218406, or from the webcast link in the investor relations section of the company's website at

      8/1/24 4:05:00 PM ET
      $RVNC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Revance to Release First Quarter 2024 Financial Results on Thursday, May 9, 2024

      Conference Call Scheduled for Thursday, May 9, 2024 at 4:30 p.m. ET. Revance Therapeutics, Inc. (NASDAQ:RVNC), today announced that the company will release first quarter 2024 financial results on Thursday, May 9, 2024, after the close of market. Revance will host a corresponding conference call and a live webcast at 1:30 p.m. PT / 4:30 p.m. ET on the same day to discuss the results and provide a corporate update. Individuals interested in listening to the conference call may do so by dialing (833) 470-1428 for U.S callers and (929) 526-1599 for other locations and reference conference ID 663066, or from the webcast link in the investor relations section of the company's website at www.

      5/2/24 4:05:00 PM ET
      $RVNC
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $RVNC
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Revance Therapeutics Inc.

      SC 13G/A - Revance Therapeutics, Inc. (0001479290) (Subject)

      10/23/24 7:17:03 PM ET
      $RVNC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Revance Therapeutics Inc.

      SC 13G/A - Revance Therapeutics, Inc. (0001479290) (Subject)

      10/7/24 10:08:00 AM ET
      $RVNC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by Revance Therapeutics Inc.

      SC 13G - Revance Therapeutics, Inc. (0001479290) (Subject)

      9/16/24 5:01:08 PM ET
      $RVNC
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $RVNC
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Crown Laboratories Completes Acquisition of Revance Therapeutics

      Yesterday, Crown Laboratories, Inc. ("Crown"), a Hildred Capital portfolio company and privately held, global innovative leader in the skincare industry, announced the closing of its acquisition of Revance Therapeutics, Inc. ("Revance") (NASDAQ:RVNC), a biotechnology company aimed at setting the new standard in healthcare with innovative aesthetic and therapeutic offerings. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250207314086/en/ Jeff Bedard, Founder and Chief Executive Officer of Crown commented, "We are excited to officially welcome Revance to the Crown family. This acquisition strengthens our leadership position and en

      2/7/25 3:46:00 PM ET
      $RVNC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Crown Laboratories Announces Completion of Acquisition of Revance Therapeutics

      The business combination reinforces Crown's position as a leading, innovative, high-growth aesthetics and skincare company JOHNSON CITY, Tenn., Feb. 6, 2025 /PRNewswire/ -- Crown Laboratories, Inc. ("Crown"), a privately held, global innovative leader in the skincare industry, today announced the successful closing of its acquisition of Revance Therapeutics, Inc. ("Revance") (NASDAQ:RVNC), a biotechnology company aimed at setting the new standard in healthcare with innovative aesthetic and therapeutic offerings. The Offer and the Merger Crown's tender offer to acquire all of

      2/6/25 8:39:00 AM ET
      $RVNC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Crown Laboratories and Revance Therapeutics Announce Expiration of Tender Offer

      JOHNSON CITY, Tenn. and NASHVILLE, Tenn., Feb. 5, 2025 /PRNewswire/ -- Crown Laboratories, Inc. ("Crown") and Revance Therapeutics, Inc. (NASDAQ:RVNC) ("Revance"), today announced that the tender offer to purchase all of the issued and outstanding shares of common stock, par value $0.001 per share ("Shares") of Revance at a purchase price of $3.65 per Share, net to the stockholder in cash without interest and less any required tax withholding (the "Offer"), expired as scheduled at one minute past 11:59 p.m., Eastern Time, on February 4, 2025 and was not extended (such date and time, the "Expiration Time").

      2/5/25 8:00:00 AM ET
      $RVNC
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $RVNC
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    See more
    • FDA Approval for DAXXIFY issued to REVANCE THERAPEUTICS, INC.

      Submission status for REVANCE THERAPEUTICS, INC.'s drug DAXXIFY (SUPPL-2) with active ingredient DAXIBOTULINUMTOXINA-LANM has changed to 'Approval' on 08/11/2023. Application Category: BLA, Application Number: 761127, Application Classification:

      8/14/23 4:38:56 AM ET
      $RVNC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • FDA Approval for DAXXIFY issued to REVANCE THERAPEUTICS, INC.

      Submission status for REVANCE THERAPEUTICS, INC.'s drug DAXXIFY (ORIG-1) with active ingredient daxibotulinumtoixnA-lanm has changed to 'Approval' on 09/07/2022. Application Category: BLA, Application Number: 761127, Application Classification:

      9/8/22 1:11:06 PM ET
      $RVNC
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $RVNC
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Gangolli Julian S returned 15,000 shares to the company, closing all direct ownership in the company (SEC Form 4)

      4 - Revance Therapeutics, Inc. (0001479290) (Issuer)

      2/6/25 8:06:31 PM ET
      $RVNC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • President & CEO Foley Mark J returned 112,619 shares to the company and was granted 84,686 shares, closing all direct ownership in the company (SEC Form 4)

      4 - Revance Therapeutics, Inc. (0001479290) (Issuer)

      2/6/25 3:59:42 PM ET
      $RVNC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • CFO Schilke Tobin returned 124,438 shares to the company and was granted 20,883 shares, closing all direct ownership in the company (SEC Form 4)

      4 - Revance Therapeutics, Inc. (0001479290) (Issuer)

      2/6/25 3:59:07 PM ET
      $RVNC
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $RVNC
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Revance Therapeutics downgraded by Mizuho with a new price target

      Mizuho downgraded Revance Therapeutics from Buy to Neutral and set a new price target of $9.00 from $16.00 previously

      1/29/24 7:24:59 AM ET
      $RVNC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Revance Therapeutics downgraded by Goldman with a new price target

      Goldman downgraded Revance Therapeutics from Buy to Neutral and set a new price target of $8.00 from $30.00 previously

      1/9/24 8:27:15 AM ET
      $RVNC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Revance Therapeutics upgraded by Exane BNP Paribas with a new price target

      Exane BNP Paribas upgraded Revance Therapeutics from Underperform to Neutral and set a new price target of $20.00

      8/16/23 8:52:06 AM ET
      $RVNC
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $RVNC
    Leadership Updates

    Live Leadership Updates

    See more
    • Nanostics Announces New Member of Board of Directors

      EDMONTON, AB, Nov. 17, 2022 /PRNewswire/ - Nanostics Inc., a precision health diagnostics company, announced today the appointment of Aubrey Rankin to its Board of Directors. Mr. Rankin will join the board of directors at Nanostics replacing Mr. Reg Joseph as one of the independent directors for the company. "We're excited to announce Aubrey Rankin's appointment to Nanostics' Board of Directors. Aubrey's vast experience and insights with patient-provider subscription platforms will be invaluable as we launch our lead prostate cancer diagnostic test, ClarityDX Prostate®," said

      11/17/22 8:00:00 AM ET
      $RVNC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Revance Reports First Quarter 2021 Financial Results, Provides Corporate Update

      - Q1 revenue for the RHA® Collection of dermal fillers of $11.6 million - HintMD's processing volume run-rate more than doubled to over $400 million from the prior quarter - Over 1,500 aesthetic accounts activated across products and services at quarter-end - Status of the U.S. Food and Drug Administration (FDA) pre-approval inspection - Conference call and webcast today at 4:30 p.m. ET Revance Therapeutics, Inc. (NASDAQ:RVNC), a biotechnology company focused on innovative aesthetic and therapeutic offerings, today reported financial results for the first quarter ended March 31, 2021 and provided a corporate update. Financial Highlights Revenue for the first quarter 2021 totaled $

      5/10/21 4:05:00 PM ET
      $RVNC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Ambrx Appoints Audit Executive Chris Nolet to Board of Directors

      SAN DIEGO--(BUSINESS WIRE)--​Ambrx, a clinical stage biopharmaceutical company using an expanded genetic code to create Engineered Precision Biologics, today announced the appointment of Chris Nolet to the company’s Board of Directors. Mr. Nolet brings extensive experience as a long-time audit partner and business advisor in the life sciences industry, and has assumed the role of Chair of Ambrx’s Audit Committee. “We are delighted that Chris will be joining our Board of Directors given his deep expertise, knowledge base and industry network,” said Feng Tian, Ph.D., President and CEO of Ambrx. “His experience in helping transition clinical stage companies into commercially integra

      2/23/21 4:05:00 PM ET
      $VIE
      $PTE
      $RVNC
      Major Pharmaceuticals
      Health Care
      Biotechnology: Biological Products (No Diagnostic Substances)
      Biotechnology: Pharmaceutical Preparations

    $RVNC
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Foley Mark J bought $209,400 worth of shares (30,000 units at $6.98), increasing direct ownership by 3% to 1,015,468 units (SEC Form 4)

      4 - Revance Therapeutics, Inc. (0001479290) (Issuer)

      3/8/24 4:33:10 PM ET
      $RVNC
      Biotechnology: Pharmaceutical Preparations
      Health Care